FI℞ST® – BXN Mouthwash Unit-of-Use compounding kit makes pharmacy compounding easier
Woburn, Mass., September 22, 2009 – CutisPharma, Inc. announced the introduction of FI℞ST® – BXN Mouthwash. It is the second in the FIRST® Mouthwash Compounding Kit product line, which already includes FI℞ST® – Mouthwash BLM. The active ingredients in FI℞ST® – BXN Mouthwash are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl®, Xylocaine 2% viscous®, and nystatin. The kits are made for one patient and include pre-weighed diphenhydramine hydrochloride, lidocaine hydrochloride, and nystatin powder, and a pre-measured suspension. With FI℞ST® – BXN Mouthwash, the pharmacist needs only to add the powders to the liquid suspension, shake, and then dispense to the patient.
“By launching FI℞ST® – BXN, physicians now have two of the more commonly prescribed magic mouthwash prescriptions available in a kit,” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “The Company anticipates launching two additional Mouthwash products, FI℞ST® – Mary’s Mouthwash, and FI℞ST® – Duke’s Mouthwash, in the near future, thus completing the Mouthwash product line.”
FI℞ST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FI℞ST® Mouthwash kits, the pharmacist can compound a prescription faster than those prepared in the conventional way. A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.
CutisPharma now has ten proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and two Magic Mouthwash kits. Several more compounding kits are in the planning stages. FI℞ST® Unit-of-Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>.
The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FI℞ST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.
V.P. Business Development